GLPG Share Price Performance
€0
-25.54 (-100.00%)
Price €0
Fair Value€44.80
Share Pricen/a
Galapagos NV Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
GLPG Community Narratives
AN
Fair Value €44.8 38.5% undervalued intrinsic discount
Cell Therapy Wind Down And Cash Reserves Will Drive A Leaner, Stronger Biotech Future
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Cell Therapy Wind Down And Cash Reserves Will Drive A Leaner, Stronger Biotech Future
Catalysts About Galapagos Galapagos is a biotechnology company focused on using its substantial capital base and deal-making expertise to build a differentiated, late stage therapeutic pipeline. What are the underlying business or industry changes driving this perspective?Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€44.8
38.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
0.57% p.a.
Profit Margin
1.25%
Future PE
9.62x
Price in 2028
€0.53
Trending Discussion
Recently Updated Narratives
AN
Cell Therapy Wind Down And Cash Reserves Will Drive A Leaner, Stronger Biotech Future
Fair Value: €44.8 38.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Galapagos NV Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 23, 2026
- -6.74
- -72.21%
- -154.70%
- 0%
About GLPG
- Founded
- 1999
- Employees
- 558
- CEO
- WebsiteView website
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
